| Background | Sibrotuzumab (also known as BIBH 1) is a humanized monoclonal antibody (mAb) which has the high affinity to bind to fibroblast activation protein (FAP), which is highly expressed by stroma cells of tumors. In addition, it was intended and developed by Boehringer Ingelheim Pharma KG for the treatment of cancer. Firstly, this drug was designed to fight against various malignancies, such as colorectal, non-small cell lung, breast, as well as head and neck cancer. However, it is disappointing that in 2003 it failed a phase II clinical trial for metastatic colorectal cancer. At present, there is no relevant clinically approved information disclosure. |
|---|
